Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of FMR-1 Gene Defects and other Pediatric Syndromal Disorders Associated with Cognitive Impairment

References (43)

1. 1 Prader-Willi syndrome. [DOI]
2. 2 Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety [DOI]
3. 3 Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update [DOI]
4. 4 Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial [DOI]
5. 5 Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction [DOI]
6. 6 Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease [DOI]
7. 7 Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial [DOI]
8. 8 Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease [DOI]
9. 9 Global prevalence of Rett syndrome: systematic review and meta-analysis [DOI]
10. 10 Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders [DOI]
11. 11 Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease [DOI]
12. 12 PDE4 subtypes in cancer [DOI]
13. 13 Genetic Landscape of Rett Syndrome Spectrum: Improvements and Challenges [DOI]
14. 14 The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches [DOI]
15. 15 Multidisciplinary Management of Rett Syndrome: Twenty Years’ Experience [DOI]
16. 16 Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease [DOI]
17. 17 Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice [DOI]
18. 18 Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D) [DOI]
19. 19 Prader–Willi Syndrome and Hypogonadism: A Review Article [DOI]
20. 20 Phosphodiesterase‐4 inhibition as a therapeutic strategy for metabolic disorders [DOI]
21. 21 Small Molecule Allosteric Modulators of Phosphodiesterase 4 [DOI]
22. 22 Rett syndrome before regression: A time window of overlooked opportunities for diagnosis and intervention [DOI]
23. 23 A Novel PDE4D Inhibitor BPN14770 Reverses Scopolamine-Induced Cognitive Deficits via cAMP/SIRT1/Akt/Bcl-2 Pathway [DOI]
24. 24 Inhibition of PDE4/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury [DOI]
25. 25 Rett Syndrome Spectrum in Monogenic Developmental-Epileptic Encephalopathies and Epilepsies: A Review [DOI]
26. 26 Ablation of specific long PDE4D isoforms increases neurite elongation and conveys protection against amyloid-β pathology [DOI]
27. 27 Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential [DOI]
28. 28 Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse) [DOI]
29. 29 Effects of chronic inhibition of phosphodiesterase-4D on behavior and regional rates of cerebral protein synthesis in a mouse model of fragile X syndrome [DOI]
30. 30 Efficacy of Selective PDE4D Negative Allosteric Modulators in the Object Retrieval Task in Female Cynomolgus Monkeys (Macaca fascicularis) [DOI]
31. 31 Treatment with the selective PDE4B inhibitor A-33 or PDE4D inhibitor zatolmilast prevents sleep deprivation-induced deficits in spatial pattern separation [DOI]
32. 32 Gene Editing and Rett Syndrome: Does It Make the Cut? [DOI]
33. 33 Amelioration of functional and histopathological consequences after spinal cord injury through phosphodiesterase 4D (PDE4D) inhibition [DOI]
34. 34 Biarylcarboxylic Acids and -amides: Inhibition of Phosphodiesterase Type IV versus [3H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret [DOI]
35. 35 Rett syndrome [DOI]
36. 36 Special Issue: Genetics of Prader–Willi Syndrome [DOI]
37. 37 Characterization of the Cellular Activity of PDE 4 Inhibitors Using Two Novel PDE 4 Reporter Cell Lines [DOI]
38. 38 Advances in the pathogenesis of Rett syndrome using cell models [DOI]
39. 39 Differential effects of two phosphodiesterase 4 inhibitors against lipopolysaccharide-induced neuroinflammation in mice [DOI]
40. 40 Allosteric inhibition of phosphodiesterase 4D induces biphasic memory-enhancing effects associated with learning-activated signaling pathways [DOI]
41. 41 Allosteric regulatory properties of muscle phosphofructokinase [DOI]
42. 42 A Rare Case of an Infant With 1p36 Deletion Syndrome Presenting With Systolic Heart Failure Secondary to Severe Dilated Cardiomyopathy [DOI]
43. 43 Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders [DOI]

Cited by 0

No indexed citations yet.